Lund, Sweden - 12 April 2011 - BioInvent International AB (OMXS: BINV) has appointed Sten Westerberg to a new position as Vice President Investor Relations. Sten is today sector head at Öhman Fondkommission, Healthcare Equity Research. He previously held positions as pharmaceutical analyst at Swedbank Markets and stock market journalist at the Veckans Affärer.

"We are very pleased to have recruited Sten who has a long experience in capital markets with focus on the pharmaceutical industry" comments BioInvent's CEO Svein Mathisen the appointment.

"BioInvent is at an exciting stage with several drug candidates advancing in the clinical trials. I look forward to working with Sten to further increase the awareness of BioInvent."

-- END --

Notes to Editors:

About BioInvent
BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and increase the likelihood of success. These partners include Genentech, Human Genome Sciences, Roche and ThromboGenics.

The company's competitive position is underpinned by an in substance patented antibody development platform. The scope and strength of this platform is also utilised by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA.

More information is available at www.bioinvent.com (http://www.bioinvent.com).
 
 

For further information, please contact:

BioInvent International AB
Svein Mathisen    
President & CEO 
Tel: +46 (0)46-286 85 67    
Mobile: +46 (0)708-97 82 13        *
E-mail: [email protected] ([email protected])                   

Cristina Glad
Executive Vice President
Tel: +46 (0)46-286 85 51
Mobile: +46 (0)708-16 85 70
E-mail: [email protected] ([email protected])

College Hill (media enquiries)
Melanie Toyne Sewell, Anastasios Koutsos
Tel: +44 (0)20 7866 7856
Rebecca Skye Dietrich
Tel: +1 (857) 241-0795
E-mail: [email protected] ([email protected])

BioInvent International AB (publ)        
Co. reg. No. 556537-7263,      
Address:  Sölvegatan 41     
Mailing address: SE-223 70 LUND  
Tel: +46 (0)46 286 85 50 
[email protected] ([email protected])      
www.bioinvent.com (http://www.bioinvent.com/)                    

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.45 a.m. CET, on 12 April, 2011.